Summary & Overview
CPT 38227: Ex Vivo Genetic Modification of Cryopreserved T Lymphocytes
CPT code 38227 covers the laboratory service of receiving cryopreserved T lymphocytes and genetically modifying them for subsequent administration in CAR–T cell therapy. This procedure is a core part of autologous cellular immunotherapy workflows and is critical to the delivery of personalized cancer treatments. Nationally, growing use of CAR–T therapies makes accurate coding and coverage understanding important for hospitals, specialty labs, and payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how 38227 is used in clinical practice, typical sites of service, and the service type it represents. The publication also summarizes benchmark considerations and common policy themes seen across major payers and Medicare, as well as clinical context for why ex vivo T‑cell modification is billed separately from collection and infusion services.
This executive summary prepares clinicians, coding professionals, and policy analysts to understand where 38227 fits within CAR–T procedural episodes, what documentation elements support the code, and what topics to monitor—such as coverage policies, coding bundles, and laboratory accreditation—that affect access and reimbursement for advanced cellular therapies.
Billing Code Overview
CPT code 38227 describes when a laboratory receives cryopreserved T lymphocytes (white blood cells) and genetically modifies them for later administration as part of CAR–T cell therapy. This service involves ex vivo manipulation of a patient’s collected T cells to express chimeric antigen receptors or other genetic modifications intended to target disease.
-
Service type: Laboratory processing and genetic modification of cryopreserved T lymphocytes for therapeutic use
-
Typical site of service: Specialized clinical laboratory or cell-processing facility associated with an academic medical center, hospital system, or licensed cellular therapy manufacturer
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory B-cell malignancy (for example diffuse large B-cell lymphoma) who previously underwent leukapheresis to collect autologous T lymphocytes. The patient’s cryopreserved T cells are shipped to a specialized laboratory that performs ex vivo genetic modification and expansion to produce chimeric antigen receptor T cells (CAR–T). The laboratory receives the cryopreserved specimen, performs cell thawing, transduction with a viral vector (commonly lentiviral or retroviral), cell culture and expansion, quality control testing (including sterility, viability, transduction efficiency, and release criteria), and cryopreservation of the final drug product for return to the treating facility. The treating facility then administers lymphodepleting chemotherapy, schedules infusion of the modified cells, and monitors for acute toxicities such as cytokine release syndrome and neurotoxicity. Typical site of service for the laboratory processing is an accredited cellular therapy or GMP-compliant cell processing laboratory; the clinical administration occurs in an inpatient or outpatient infusion center experienced in CAR–T therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no additional modifier is applicable to the service. |
22 |